Future cancer drugs that are activated by light and don't cause the toxic side-effects of current chemotherapy treatments are closer to becoming a reality, thanks to new research by the University of Warwick and Monash University
Led by Robbin Vernooij, a joint PhD student from the Monash Warwick Alliance, fresh insight has been gained into how a pioneering platinum-based chemotherapy drug candidate functions when activated by light.
The treatment - originally developed by Professor Peter Sadler's research group in the University of Warwick's Department of Chemistry - is an inorganic-metal compound with an unusual mechanism, which kills cancer cells in specific targeted areas, in an effort to minimize toxic side-effects on healthy tissue.
Completely inactive and non-toxic in the dark, the treatment can be inserted into cancerous areas, its functions triggered only when directed light hits it - causing the compound to degrade into active platinum and releasing ligand molecules to attack cancer cells.
Using an old spectroscopic technique - infrared spectroscopy - the researchers observed what happens to the structure of the compound by following the metal as well as molecules released from the compound.
The researchers shone infrared light on the inorganic-metal compound in the laboratory, and measured the vibrations of its molecules as it was activated.
From this, they discovered the chemical and physical properties of the compound: some of the organic ligands, which are attached to the metal atoms of the compound, become detached and are replaced with water whilst other ligands remain stable around the metal.
This fresh insight into the mechanics of the treatment offers new hope that photoactive chemotherapy drug candidates will progress from the laboratory to future clinical trials.
- Cancer drugs activated by light, minimizing toxic side-effects, are a step closer thanks to new research from University of Warwick and Monash University through the Monash Warwick Alliance
- Platinum-based chemotherapy drug candidate kills cancer cells in specific targeted areas, and totally inactive unless triggered by light - minimises harm towards healthy tissue
- Researchers used infrared spectroscopy, an old spectroscopic technique showing a resurgence in recent years, to discover how the anticancer therapy uniquely functions upon activation with light
Led by Robbin Vernooij, a joint PhD student from the Monash Warwick Alliance, fresh insight has been gained into how a pioneering platinum-based chemotherapy drug candidate functions when activated by light.
The treatment - originally developed by Professor Peter Sadler's research group in the University of Warwick's Department of Chemistry - is an inorganic-metal compound with an unusual mechanism, which kills cancer cells in specific targeted areas, in an effort to minimize toxic side-effects on healthy tissue.
Completely inactive and non-toxic in the dark, the treatment can be inserted into cancerous areas, its functions triggered only when directed light hits it - causing the compound to degrade into active platinum and releasing ligand molecules to attack cancer cells.
Using an old spectroscopic technique - infrared spectroscopy - the researchers observed what happens to the structure of the compound by following the metal as well as molecules released from the compound.
The researchers shone infrared light on the inorganic-metal compound in the laboratory, and measured the vibrations of its molecules as it was activated.
From this, they discovered the chemical and physical properties of the compound: some of the organic ligands, which are attached to the metal atoms of the compound, become detached and are replaced with water whilst other ligands remain stable around the metal.
This fresh insight into the mechanics of the treatment offers new hope that photoactive chemotherapy drug candidates will progress from the laboratory to future clinical trials.
RSS Feed